Oxytocin
( DrugBank: Oxytocin / KEGG DRUG: Oxytocin )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 127 | Frontotemporal lobar degeneration | 5 |
| 168 | Ehlers-Danlos syndrome | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 193 | Prader-Willi syndrome | 23 |
| 226 | Interstitial cystitis with Hunners ulcer | 1 |
127. Frontotemporal lobar degeneration
Clinical trials : 123 / Drugs : 107 - (DrugBank : 33) / Drug target genes : 49 - Drug target pathways : 89
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
168. Ehlers-Danlos syndrome
Clinical trials : 16 / Drugs : 22 - (DrugBank : 10) / Drug target genes : 11 - Drug target pathways : 103
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
193. Prader-Willi syndrome
Clinical trials : 128 / Drugs : 94 - (DrugBank : 25) / Drug target genes : 51 - Drug target pathways : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
226. Interstitial cystitis with Hunners ulcer
Clinical trials : 163 / Drugs : 158 - (DrugBank : 58) / Drug target genes : 79 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|